Does the PACIFIC trial show an overall survival benefit for patients with unresectable stage III non‑small cell lung cancer who have completed concurrent chemoradiotherapy and have an ECOG performance status of 0‑1?

Yes, the PACIFIC trial demonstrates a clear and substantial overall survival benefit.

The PACIFIC trial provides level 1 evidence showing that consolidation durvalumab after concurrent chemoradiotherapy significantly improves overall survival in patients with unresectable stage III NSCLC, with a median OS of 47.5 months versus 29.1 months for placebo (HR 0.72,95% CI 0.59-0.89). 1

Magnitude of Survival Benefit

The survival advantage is both statistically significant and clinically meaningful:

• Median OS improvement: 18.4 months longer (47.5 vs 29.1 months)
• 5-year OS rates: 42.9% with durvalumab versus 33.4% with placebo—an absolute improvement of 9.5% 2
• Hazard ratio for death: 0.68 (99.73% CI 0.47-0.997, P=0.0025) 3

This translates to approximately one in three patients treated with durvalumab remaining alive and progression-free at 5 years (33.1% vs 19.0% with placebo) 2. The 2022 ASCO guidelines explicitly state this trial "provides level 1 evidence demonstrating a survival benefit" and recommend consolidation durvalumab with strong recommendation strength and high-quality evidence 1.

Progression-Free Survival Benefits

Beyond OS, the trial showed dramatic PFS improvements:

• Median PFS: 16.8-17.2 months with durvalumab versus 5.6 months with placebo (HR 0.52-0.55) 1, 2
• Reduced CNS metastases: 6.5% incidence with durvalumab versus 11.8% with placebo 4
• Time to distant metastasis: 28.3 months versus 16.2 months (HR 0.53) 3

Quality of Life Considerations

The survival benefit comes with acceptable toxicity:

• Grade 3-4 pneumonitis occurred in only 4.4% of durvalumab patients 1
• Overall grade 3-4 adverse events: 30.5% durvalumab versus 26.1% placebo 3
• Treatment discontinuation due to adverse events: 15.4% versus 9.8% 3

Real-world data confirms these findings, with 57.7% of patients completing the full 12-month durvalumab course and comparable safety profiles even in elderly populations 5.

Clinical Application Algorithm

For eligible patients (unresectable stage III NSCLC, ECOG 0-1, no progression after concurrent chemoradiotherapy):

1. Initiate durvalumab within 42 days of completing chemoradiotherapy 1
2. Continue for up to 12 months unless disease progression or unacceptable toxicity occurs
3. Monitor for pneumonitis as the primary higher-grade toxicity

Important Caveats

The post hoc subgroup analysis suggested potential lack of benefit in:

• PD-L1 negative tumors (HR 1.05,95% CI 0.69-1.62)—though this was only 20% of the trial population 1
• EGFR-mutated patients (HR 0.97,95% CI 0.40-2.33)—only 6% of study population (n=43) 1

However, the ASCO guidelines explicitly state there is "insufficient evidence to alter the recommendation" based on these molecularly defined subgroups, as the analysis was performed in a small proportion of patients 1. For EGFR-mutated patients specifically, the 2025 NCCN guidelines now recommend osimertinib consolidation instead, based on the LAURA trial showing median PFS of 39.1 versus 5.6 months 4.

Guideline Endorsement

Both ASCO (2022) and NCCN (2025) guidelines provide Category 1 recommendations for durvalumab consolidation in this setting, reflecting the highest level of evidence and consensus 1, 4. The NCCN specifically notes this is a Category 1 option for stage III disease 4.

The survival benefit is durable, sustained through 5-year follow-up, and represents a paradigm shift in the management of unresectable stage III NSCLC 2.